Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 4:50 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Surmodics, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 45 | 19 | 39 | 61 | 55 |
Receivables | 11 | 13 | 11 | 10 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 12 | 7 | 6 | 5 |
Other Current Assets | 15 | 14 | 14 | 9 | 12 |
Total Current Assets | 87 | 58 | 70 | 87 | 81 |
Net Property & Equipment | 26 | 27 | 30 | 30 | 30 |
Investments & Advances | 0 | 0 | 2 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 6 | 7 | 6 |
Intangibles | 69 | 69 | 83 | 40 | 40 |
Deposits & Other Assets | 4 | 5 | 4 | 4 | 2 |
Total Assets | 186 | 158 | 195 | 169 | 160 |
Liabilities & Shareholders Equity | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 10 | 10 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 15 | 13 | 12 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 4 | 5 | 5 | 9 |
Total Current Liabilities | 24 | 32 | 30 | 19 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 7 | 13 | 11 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 29 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 11 | 12 | 8 | 6 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 66 | 50 | 55 | 38 | 37 |
Shareholders Equity | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 37 | 29 | 22 | 15 | 11 |
Retained Earnings | 87 | 89 | 116 | 112 | 111 |
Other Equity | -5 | -10 | 2 | 3 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 120 | 108 | 140 | 131 | 123 |
Total Liabilities & Shareholder's Equity | 186 | 158 | 195 | 169 | 160 |
Total Common Equity | 120 | 108 | 140 | 131 | 123 |
Shares Outstanding | 14.10 | 13.90 | 13.80 | 13.60 | 13.40 |
Book Value Per Share | 8.50 | 7.80 | 10.15 | 9.64 | 9.14 |
Fiscal Year End for Surmodics, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 38 | 41 | 35 | 45 | 45 |
Receivables | 13 | 13 | 13 | 11 | 12 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 15 | 14 | 15 | 15 |
Other Current Assets | 13 | 15 | 17 | 15 | 15 |
Total Current Assets | 80 | 84 | 80 | 87 | 86 |
Net Property & Equipment | 25 | 26 | 26 | 26 | 27 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 67 | 68 | 71 | 69 | 72 |
Deposits & Other Assets | 5 | 4 | 4 | 4 | 5 |
Total Assets | 177 | 183 | 180 | 186 | 189 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 10 | 17 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 12 |
Other Current Liabilities | 4 | 5 | 4 | 4 | 4 |
Total Current Liabilities | 20 | 19 | 16 | 24 | 32 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 4 | 4 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 29 | 29 | 29 | 29 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 9 | 8 | 10 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 59 | 59 | 58 | 66 | 76 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 42 | 40 | 38 | 37 | 34 |
Retained Earnings | 79 | 87 | 86 | 87 | 81 |
Other Equity | -4 | -4 | -3 | -5 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 118 | 124 | 122 | 120 | 112 |
Total Liabilities & Shareholder's Equity | 177 | 183 | 180 | 186 | 189 |
Total Common Equity | 118 | 124 | 122 | 120 | 112 |
Shares Outstanding | 14.20 | 14.20 | 14.20 | 14.10 | 14.10 |
Book Value Per Share | 8.32 | 8.73 | 8.60 | 8.50 | 7.97 |